Acadia Healthcare (NASDAQ:ACHC – Get Free Report) and bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.
Valuation & Earnings
This table compares Acadia Healthcare and bioAffinity Technologies”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Acadia Healthcare | $3.31 billion | 0.77 | -$1.10 billion | ($12.45) | -2.21 |
| bioAffinity Technologies | $6.16 million | 0.87 | -$14.91 million | ($109.45) | -0.08 |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Acadia Healthcare and bioAffinity Technologies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Acadia Healthcare | 2 | 5 | 7 | 1 | 2.47 |
| bioAffinity Technologies | 1 | 0 | 0 | 0 | 1.00 |
Acadia Healthcare presently has a consensus price target of $29.85, suggesting a potential upside of 8.53%. Given Acadia Healthcare’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Acadia Healthcare is more favorable than bioAffinity Technologies.
Volatility and Risk
Acadia Healthcare has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, bioAffinity Technologies has a beta of -1.11, suggesting that its stock price is 211% less volatile than the S&P 500.
Profitability
This table compares Acadia Healthcare and bioAffinity Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Acadia Healthcare | -33.44% | 6.19% | 2.42% |
| bioAffinity Technologies | -257.30% | -220.52% | -136.76% |
Insider and Institutional Ownership
1.6% of bioAffinity Technologies shares are owned by institutional investors. 1.2% of Acadia Healthcare shares are owned by insiders. Comparatively, 2.7% of bioAffinity Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Acadia Healthcare beats bioAffinity Technologies on 10 of the 15 factors compared between the two stocks.
About Acadia Healthcare
Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.
About bioAffinity Technologies
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.
Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
